Clinics in Dermatology
Volume 27, Issue 5 , Pages 435-445 , September 2009

Common cosmeceuticals

References 

  1. Davies PJA, Basilion JP, Haake AR. Intrinsic biology of retinoids in the skin. In:  Goldsmith LA editors. Physiology, biochemistry, and molecular biology of the skin. New York: Oxford University Press; 1997;p. 385–409
  2. Varani J, Fisher GJ, Kang S, et al. Molecular mechanisms of intrinsic skin aging and retinoid-induced repair and reversal. J Invest Dermatol Symp Proc. 1998;3:57–60
  3. Kang S, Duell EA, Fisher GJ, et al. Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels of irritation. J Invest Dermatol. 1995;105:549–556
  4. Smith TJ. Retinoic acid inhibition of hyaluronate synthesis in cultured human skin fibroblasts. J Clin Endocrinol Metab. 1990;70:655–660
  5. Gonzalez S, Moran M, Kochevar IE. Chronic photodamage in skin of mast cell-deficient mice. Photochem Photobiol. 1999;70:248–253
  6. Dunstan RW, Kennis RA. Selected heritable skin diseases of domesticated animals. In:  Sundberg JP editors. Handbook of mouse mutations with skin and hair abnormalities. Boca Raton: CRC Press; 1994;p. 524–525
  7. Kligman AM, Baker TJ, Gordon HL. Long-term histologic follow-up of phenol face peels. Plast Reconstruct Surg. 1975;75:652–659
  8. Reynolds NJ, Fisher GJ, Griffiths CE, et al. Retinoic acid metabolites exhibit biological activity in human keratinocytes, mouse melanoma cells and hairless mouse skin in vivo. J Pharmacol Exp Ther. 1993;266:1636–1642
  9. Gendimenico GJ, Mezick JA. Pharmacological effects of retinoids on skin cells. Skin Pharmacol. 1993;6S:24–34
  10. Griffiths CE, Finkel LJ, Tranfaglia MG, et al. An in vivo experimental model for effects of topical retinoic acid in human skin. Br J Dermatol. 1993;129:389–394
  11. Oblong JE, Bissett DL. Retinoids. In:  Draelos ZD editors. Cosmeceuticals. Philadelphia: Elsevier Saunders; 2005;p. 35–42
  12. Creidi P, Humbert P. Clinical use of topical retinaldehyde on photoaged skin. Dermatol. 1999;199S:49–52
  13. Diridollou S, Vienne MP, Alibert M, et al. Efficacy of topical 0.05% retinaldehyde in skin aging by ultrasound and rheological techniques. Dermatol. 1999;199S:37–41
  14. Creidi P, Vienne MP, Ochonishy S, et al. Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol. 1998;39:960–965
  15. Erling T. Skin treatment with two different galenical formulations of retinyl palmitate in humans. J Appl Cosmetol. 1993;11:71–76
  16. Fluhr JW, Vienne MP, Lauze C, et al. Tolerance profile of retinol, retinaldehyde, and retinoic acid under maximized and long-term clinical conditions. Dermatol. 1999;199S:57–60
  17. Matts PJ, Oblong JE, Bissett DL. A review of the range of effects of niacinamide in human skin. Intl Fed Soc Cosmet Chem Mag. 2002;5:285–289
  18. Bissett DL. Topical niacinamide and barrier enhancement. Cutis. 2002;70S:8–12
  19. Bissett DL, Oblong JE, Saud A, et al. Topical niacinamide provides skin aging appearance benefits while enhancing barrier function. J Clin Dermatol. 2003;32S:9–18
  20. Draelos ZD, Matsubara A, Smiles K. The effect of 2% niacinamide on facial sebum production. J Cos Laser Ther. 2006;8:96–101
  21. Draelos ZD, Ertel K, Berge C. Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis. 2005;76:135–141
  22. Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147:22–33
  23. Greatens A, Hakozaki T, Koshoffer A, et al. Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Exp Dermatol. 2005;14:498–508
  24. Bissett DL, Miyamoto K, Sun P, et al. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci. 2004;26:231–238
  25. Tanno O, Ota Y, Kitamura N, et al. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol. 2000;143:525–531
  26. Griffiths CEM. Nicotinamide 4% gel for the treatment of inflammatory acne vulgaris. J Dermatol Treat. 1995;6S:8–10
  27. Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003;131:48–52
  28. Gebicki J, Sysa-Jedrzejowska A, Adamus J, et al. 1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin. Pol J Pharmacol. 2003;55:109–112
  29. Reber F, Geffarth R, Kasper M, et al. Graded sensitiveness of the various retinal neuron populations on the glyoxal-mediated formation of advanced glycation end products and ways of protection. Graefes Arch Clin Exp Ophthalmol. 2003;241:213–225
  30. Thornalley PJ. Glycation in diabetic reuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002;50:37–57
  31. Jacobson MK, Kim H, Kim M, et al. Modulating NAD-dependent DNA repair and transcription regulated pathways of skin homeostatis: evaluation in human subjects. Poster In: Presented at: American Academy of Dermatology Annual Meeting. 2002;
  32. Andersson RG, Aberg G, Brattsand R, et al. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol. 1977;41:1–10
  33. Alster TS, West TB. Effect of topical vitamin C on postoperative carbon dioxide laser resurfacing erythema. Dermatol Surg. 1998;24:331–334
  34. Tajima S, Pinnell SR. Ascorbic acid preferentially enhances type I and III collagen gene transcription in human skin fibroblasts. J Dermatol Sci. 1996;11:250–253
  35. Phillips CL, Combs SB, Pinnell SR. Effects of ascorbic acid on proliferation and collagen synthesis in relation to the donor age of human dermal fibroblasts. J Invest Dermatol. 1994;103:228–232
  36. Geesin JC, Darr D, Kaufman R, et al. Ascorbic acid specifically increases type I and type III pro-collagen messenger RNA levels in human skin fibroblasts. J Invest Dermatol. 1998;90:420–424
  37. Pinnell SR. Regulation of collagen biosynthesis by ascorbic acid: a review. Yale J Biol Med. 1985;58:553–559
  38. Raschke T, Koop U, Dusing HJ, et al. Topical activity of ascorbic acid: from in vitro optimization to in vivo efficacy. Skin Pharmacol Physiol. 2004;17:200–206
  39. Fitzpatrick RE, Rostan EF. Double-blind, half-face study comparing topical vitamin C and vehicle for rejuvenation of photodamage. Dermatol Surg. 2002;28:231–236
  40. Humbert PG, Haftek M, Creidi P, et al. Topical ascorbic acid on photoaged skin: clinical, topographical and ultrastructural evaluation: double-blind study vs. placebo. Exptl Dermatol. 2003;12:237–244
  41. Traikovich SS. Use of topical ascorbic acid and its effects on photodamaged skin topography. Arch Otolaryngol Head Neck Surg. 1999;125:1091–1098
  42. Thiele JJ, Ekanayake-Mudiyanselage S, Hsieh SN. In:  Draelos ZD editors. Cosmeceutical vitamins: vitamin E. Elsevier Saunders: Cosmeceuticals. Philadelphia; 2005;p. 43–50
  43. Burke KE. Topical nutritional antioxidants. In:  Draelos ZD,  Thaman LA editor. Cosmetic formulation of skin care products. New York: Taylor & Francis; 2006;p. 377–402
  44. Dreher F, Gabard B, Schwindt DA, et al. Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema: a human study in vivo. Br J Dermatol. 1998;139:332–339
  45. Moeller VH, Ansmann A, Wallat S. Topical application of vitamin E and its effects on the skin. Fett Wissenschaft Technol. 1989;91:295–305
  46. Katayama K, Armendariz-Borunda J, Raghow R, et al. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268:9941–9944
  47. Robinson L, Fitzgerald N, Berge C, et al. Pentapeptide offers improvement in human photoaged facial skin. Ann Dermatol Venereol. 2002;129:1S405
  48. Lintner K, Mas-Chamberlin C, Mondon P. Pentapeptide facilitates matrix regeneration of photoaged skin. Ann Dermatol Venereol. 2002;129:1S401
  49. Lintner K. Promoting ECM production without compromising barrier. Ann Dermatol Venereol. 2002;129:1S105
  50. Bissett DL. Anti-aging skin care formulations. In:  Draelos ZD,  Thaman LA editor. Cosmetic formulation of skin care products. New York: Taylor & Francis; 2006;p. 167–186
  51. Pickart L. Copperceuticals and the skin. Cosmet Toilet. 2003;118:24–28
  52. Smith-Mungo LL, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol. 1998;16:387–398
  53. Canapp SO, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32:515–523
  54. Simeon A, Wegrowski Y, Bontemps Y, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol. 2000;115:962–968
  55. Simeon A, Emonard H, Hornebeck W, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67:2257–2265
  56. Simeon A, Monier F, Emonard H, et al. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. J Invest Dermatol. 1999;112:957–964
  57. Buffoni F, Pino R, Dal Pozzo A. Effect of tripeptide-copper complexes on the process of skin wound healing and on cultured fibroblasts. Arch Int Pharmacodyn Ther. 1995;330:345–360
  58. Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Oral presentation In: Presented at: Australian Society of Cosmetic Chemists Annual Conference. 2003;
  59. Mas-Chamberlin C, Lintner K, Basset L, et al. Relevance of antiwrinkle treatment of a peptide: 4 months clinical double blind study vs. excipient. Ann Dermatol Venereol. 2002;129:1S456
  60. Robinson LR, Fitzgerald NC, Doughty DG, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cos Sci. 2005;27:155–160
  61. Kruger N, Fiegert L, Becker D, et al. For the treatment of skin aging: trace elements in form of a complex of copper tripeptide. Cosmet Med. 2003;24:31–33
  62. Appa Y, Stephens T, Barkovic S, et al. A clinical evaluation of a copper-peptide-containing liquid foundation and cream concealer designed for improving skin condition. Poster 66 In: Presented at: American Academy of Dermatology Annual Meeting. 2002;
  63. Leyden JJ, Grove G, Barkovic S, et al. The effect of tripeptide to copper ratio in two copper peptide creams on photoaged facial skin. Poster 67 In: Presented at: American Academy of Dermatology Annual Meeting. 2002;
  64. Leyden JJ, Stephens T, Finkey MB, et al. Skin care benefits of copper peptide containing facial cream. Poster 68 In: Presented at: American Academy of Dermatology Annual Meeting. 2002;
  65. Leyden JJ, Stephens T, Finkey MB, et al. Skin care benefits of copper peptide containing eye creams. Poster 69 In: Presented at American Academy of Dermatology Annual Meeting. 2002;
  66. Foldvari M, Attah-Poku S, Hu J, et al. Palmitoyl derivatives of interferon alpha: potent for cutaneous delivery. J Pharm Sci. 1998;87:1203–1208
  67. Sauberlich HE. Pantothenic acid. In:  Goodhart RS,  Shils ME editor. Modern nutrition in health and disease. Philadelphia: Lea and Febiger; 1980;p. 209–216
  68. Ebner F, Heller A, Rippke F, et al. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3:427–433
  69. Gloor M, Senger B, Gehring W. Do dexpanthenol/glycerin combinations achieve better skin hydration than either component alone?. Aktuelle Dermatol. 2002;28:402–405
  70. Proksch E, Nissen HP. Dexpanthenol enhances skin barrier repair and reduces inflammation after sodium lauryl sulphate-induced irritation. J Dermatol Treat. 2002;13:173–178
  71. Biro K, Thaci D, Ochsendorf FR, et al. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis. 2003;49:80–84
  72. Romiti R, Romiti N. Dexpanthenol cream significantly improves mucocutaneous side effects associated with isotretinoin therapy. Pediatr Dermatol. 2002;19:368
  73. Bissett DL, Oblong JE. Cosmeceutical vitamins: vitamin B. In:  Draelos ZD editors. Cosmeceuticals. Philadelphia: Elsevier Saunders; 2005;p. 57–62
  74. Ditre CM. Exfoliants: AHAs and BHAs. In:  Draelos ZD editors. Cosmeceuticals. Philadelphia: Elsevier Saunders; 2005;p. 111–118
  75. Briden ME, Green BA. Topical exfoliation–clinical effects and formulating considerations. In:  Draelos ZD,  Thaman LA editor. Cosmetic formulation of skin care products. New York: Taylor & Francis; 2006;p. 237–250
  76. Yu RJ, Van Scott EJ. α-Hydroxyacids, polyhydroxy acids, aldobionic acids and their topical actions. In:  Baran R,  Maibach HI editor. Textbook of cosmetic dermatology. New York: Taylor & Francis; 2005;p. 77–93
  77. Uhoda E, Pierard-Franchimont C, Petit L, et al. Hydroxyacids. In:  Elsner P,  Maibach HI editor. Cosmeceuticals and active cosmetics. New York: Taylor & Francis; 2005;p. 207–218
  78. Imokawa G, Mishima Y. Analysis of tyrosinases as asparagin-linked oligosaccharides by conanavalin A lectin chromatography: appearance of new segment of tyrosinases in melanoma cells following interrupted melanogenesis induced by glycosylation inhibitors. J Invest Dermatol. 1985;85:165–168
  79. Bissett DL. Glucosamine: a review of mechanisms and clinical uses in skin health. J Cosmet Dermatol. 2006;5:309–315
  80. Osborne R, Mullins L, Robinson L. Topical N-acetyl glucosamine and niacinamide increase hyaluronan in vitro. J Am Acad Dermatol. 2006;54:AB106
  81. Bissett DL, McPhail SJ, Farmer TL, et al. Topical N-acetyl glucosamine affects pigmentation-relevant genes in in vitro genomics testing. Pig Cell Res. 2006;19:373
  82. Kikuchi K, Matahira Y. Oral N-acetylglucosamine supplementation improves skin conditions of female volunteers: clinical evaluation by a microscopic three-dimensional skin surface analyzer. J Appl Cosmetol. 2002;20:143–152
  83. Bissett DL, Robinson LR, Li JX, et al. Topical sugar amine reduces the appearance of hyperpigmented spots on human dorsal forearm and facial skin. Pig Cell Res. 2006;19:376
  84. Bissett D, Kimball A, Robinson L. Topical formulation containing N-acetyl glucosamine and niacinamide reduces the appearance of photoaging on human facial skin. J Am Acad Dermatol. 2006;54:AB43
  85. Bissett D, Robinson L, Li J, et al. Topical N-acetyl glucosamine reduces the appearance of hyperpigmented spots on human facial skin. J Am Acad Dermatol. 2006;54:AB43
  86. Bissett DL, Robinson LR, Raleigh PS, et al. Reduction in the appearance of facial hyperpigmentation by topical N-acetyl glucosamine. J Cosmet Dermatol. 2007;6:20–26
  87. Kanwischer M, Kim SY, Kim JS, et al. Evaluation of the physicochemical stability and skin permeation of glucosamine sulfate. Drug Devel Ind Pharm. 2005;31:91–97
  88. Elias PM. Physiological lipids for barrier repair in dermatology. In:  Draelos ZD editors. Cosmeceuticals. Philadelphia: Elsevier Saunders; 2005;p. 63–70
  89. Lintner K, Mas-Chamberlin C, Mondon P, et al. Cutaneous barrier repair. In:  Elsner P,  Maibach HI editor. Cosmeceuticals and active cosmetics. New York: Taylor & Francis; 2005;p. 99–128
  90. Harding CR, Moore DJ, Rawlings AV. Ceramides and the skin. In:  Baran R,  Maibach HI editor. Textbook of cosmetic dermatology. New York: Taylor & Francis; 2005;p. 171–186
  91. Rogers J, Harding C, Mayo A, et al. Stratum corneum lipids: the effect of ageing and the seasons. Arch Dermatol Res. 1996;288:765–770
  92. Imokawa G, Abe A, Jin K, et al. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin?. J Invest Dermatol. 1991;96:523–526
  93. Schwartz JR. Cosmeceutical metals. In:  Draelos ZD editors. Cosmeceuticals. Philadelphia: Elsevier Saunders; 2005;p. 89–95
  94. Hoggarth A, Waring M, Alexander J, et al. A controlled, three-part trial to investigate the barrier function and skin hydration properties of six skin protectants. Ostomy Wound Manage. 2005;51:30–42
  95. Fivenson DP. The mechanisms of action of nicotinamide and zinc in inflammatory skin disease. Cutis. 2006;77S:5–10

PII: S0738-081X(09)00121-7

doi: 10.1016/j.clindermatol.2009.05.006

Clinics in Dermatology
Volume 27, Issue 5 , Pages 435-445 , September 2009

Article Tools

* Image Usage & Resolution